CN108186870A - Ginseng oyster particle - Google Patents
Ginseng oyster particle Download PDFInfo
- Publication number
- CN108186870A CN108186870A CN201810213350.4A CN201810213350A CN108186870A CN 108186870 A CN108186870 A CN 108186870A CN 201810213350 A CN201810213350 A CN 201810213350A CN 108186870 A CN108186870 A CN 108186870A
- Authority
- CN
- China
- Prior art keywords
- oyster
- ginseng
- moschus
- qiang
- lily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Insects & Arthropods (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses ginseng oyster particles, which is characterized in that by the raw material compositing formula of following parts by weight：Ginseng 30 50, oyster 30 50, pueraria lobata 30 50, peach kernel 30 50, zaocys dhumnade 30 50, lily 30 50, dark plum 30 50, abdomen snake 30 50, the root of Dahurain angelica 30 50, Chinese cassia tree 30 50, raspberry 30 50, Qiang worm 100 120, Moschus 24, safflower 10 30, the present invention can cure mainly three high, tumours, the brain stasis of blood is blocked up, brain tumor, angina pectoris.
Description
Technical field
The present invention relates to drug formulation technical fields, particularly ginseng oyster particle.
Background technology.
Three height are hyperlipidemia, hypertension, the general name of hyperglycemia.
It for hypertension means that blood pressure is higher than normally in the circulatory system, is often referred to systemic arterial blood pressure and increases, be a kind of
Common clinical syndrome.It is normal typically to be less than 140/90 millimetres of mercury, and is more than or equal to 140/90 millimetres of mercury
Hypertension.Because it is unconsciously to occur, therefore claim " killer silently ".
Hyperlipidemia refers to blood cholesterol or triglycerides is excessively high or high-density lipoprotein cholesterol is too low, and modern medicine claims
Be dyslipidemia.It is the principal element for leading to atherosclerosis, is the risk factor of cardiovascular and cerebrovascular diseases occurrence and development.It
Incidence of occult mostly without clinical symptoms, therefore is known as " stealthy killer ".
Hyperglycemia is that glucose content is higher than normal value in body blood.It is that a self-existent pathology changes in body
Become, for diseased region in blood, lesion nature is dysglycemia.The clinical manifestation of hyperglycemia can have dominant symptom, such as
Dry thirsty, drinking a lot of water, urine is more, becomes thin；Can be recessive symptom, without apparent subjective uncomfortable.
Intracranial tumors are also known as brain tumor, intracranial tumour, refer to betide the nervous system neoplasm in cranial cavity, including originating from
Neural epithelium, peripheral nerve, meninx and reproduction cell tumour, lymph and hematopoietic neoplasm, the craniopharyngioma of sella region with
Granular cell tumor and metastatic tumo(u)r.
Angina pectoris is coronary insufficiency, caused by cardiac muscle ischemia drastically and anoxic with ictal pectoralgia
Or chest discomfort is the clinical syndrome mainly showed.Angina pectoris is that heart ischemia is reflected into the pain that body surface is felt,
Feature is shirtfront paroxysmal, squeezing property pain, can be with other symptoms, and pain is predominantly located at breastbone rear portion, before being radiated to the heart
Area and left upper extremity, labour or it is excited occur often, every time breaking-out continue 3~5 minutes, can a few days it is primary, also can a number of days
It is secondary, rest or with disappearing after nitrate esters preparation.This disease is more common in male, 40 years old or more most, it is tired, excited, be satiated with food,
It catches cold, rainy weather, acute circulatory failure etc. are common inducement.
Therefore, it is necessary to invent with a kind of in the drug for treating above-mentioned disease.
Invention content.
The purpose of the present invention is to solve the above problems, ginseng oyster particle are devised, by the original of following parts by weight
Expect compositing formula：Ginseng 30-50, oyster 30-50, pueraria lobata 30-50, peach kernel 30-50, zaocys dhumnade 30-50, lily 30-50, dark plum
30-50, abdomen snake 30-50, root of Dahurain angelica 30-50, Chinese cassia tree 30-50, raspberry 30-50, Qiang worm 100-120, Moschus 2-4, safflower 10-
30。
By the raw material compositing formula of following parts by weight：Ginseng 30, oyster 30, pueraria lobata 30, peach kernel 40, zaocys dhumnade 30, lily
30, dark plum 30, abdomen snake 30, the root of Dahurain angelica 30, Chinese cassia tree 30, raspberry 30, Qiang worm 100, Moschus 2, safflower 10.
By the raw material compositing formula of following parts by weight：Ginseng 50, oyster 50, pueraria lobata 50, peach kernel 50, zaocys dhumnade 50, lily
50, dark plum 50, abdomen snake 50, the root of Dahurain angelica 50, Chinese cassia tree 50, raspberry 50, Qiang worm 120, Moschus 4, safflower 30.
By the raw material compositing formula of following parts by weight：Ginseng 40, oyster 40, pueraria lobata 40, peach kernel 40, zaocys dhumnade 40, lily
40, dark plum 40, abdomen snake 40, the root of Dahurain angelica 40, Chinese cassia tree 40, raspberry 40, Qiang worm 110, Moschus 3, safflower 20.
Advantageous effect：
The present invention can cure mainly three high, tumours, and the brain stasis of blood is blocked up, brain tumor, angina pectoris；
Specific embodiment.
The present invention is further described：
Embodiment 1
Ginseng oyster particle, by the raw material compositing formula of following parts by weight：Ginseng 30, oyster 30, pueraria lobata 30, peach kernel 40, the black tip
Snake 30, lily 30, dark plum 30, abdomen snake 30, the root of Dahurain angelica 30, Chinese cassia tree 30, raspberry 30, Qiang worm 100, Moschus 2, safflower 10.
Production method includes the following steps：
（1）Ginseng is weighed according to required quality, oyster, pueraria lobata, peach kernel, zaocys dhumnade, lily, dark plum, abdomen snake, the root of Dahurain angelica, Chinese cassia tree,
Raspberry, Qiang worm, Moschus, safflower raw material；
（2）Various raw materials are mixed, co-ground；
（3）By the material extruding after grinding into particle；
（4）It is with packing machine that granule packaging is good, it completes；
Eating method is：3 grams are often taken, day is twice.
Embodiment 2
Ginseng oyster particle, by the raw material compositing formula of following parts by weight：Ginseng 50, oyster 50, pueraria lobata 50, peach kernel 50, the black tip
Snake 50, lily 50, dark plum 50, abdomen snake 50, the root of Dahurain angelica 50, Chinese cassia tree 50, raspberry 50, Qiang worm 120, Moschus 4, safflower 30.
Production method includes the following steps：
（1）Ginseng is weighed according to required quality, oyster, pueraria lobata, peach kernel, zaocys dhumnade, lily, dark plum, abdomen snake, the root of Dahurain angelica, Chinese cassia tree,
Raspberry, Qiang worm, Moschus, safflower raw material；
（2）Various raw materials are mixed, co-ground；
（3）By the material extruding after grinding into particle；
（4）It is with packing machine that granule packaging is good, it completes；
Eating method is：3 grams are often taken, day is twice.
Embodiment 3
Ginseng oyster particle, by the raw material compositing formula of following parts by weight：Ginseng 40, oyster 40, pueraria lobata 40, peach kernel 40, the black tip
Snake 40, lily 40, dark plum 40, abdomen snake 40, the root of Dahurain angelica 40, Chinese cassia tree 40, raspberry 40, Qiang worm 110, Moschus 3, safflower 20.
Production method includes the following steps：
（1）Ginseng is weighed according to required quality, oyster, pueraria lobata, peach kernel, zaocys dhumnade, lily, dark plum, abdomen snake, the root of Dahurain angelica, Chinese cassia tree,
Raspberry, Qiang worm, Moschus, safflower raw material；
（2）Various raw materials are mixed, co-ground；
（3）By the material extruding after grinding into particle；
（4）It is with packing machine that granule packaging is good, it completes；
Eating method is：3 grams are often taken, day is twice.
Case one：
Patient：Female, 56 years old
Symptom：Bored pain, squeezing property pain or breastbone after, bottleneck throat girdle sensation
Diagnosis：Angina pectoris
Treatment：Sublingual administration functions to, about event resolves after half an hour for 1~2 minute.
Case two：
Patient：Man, 76 years old
Symptom：Headache, vomiting, vision disorder, dizziness
Diagnosis：Intracranial tumors
Treatment：Oral, continuous treatment 5 days, 28 days are 1 period, treat 3 periods, take an evident turn for the better.
Case three：
Patient：Man, 77 years old
Symptom：Dizzy, headache, neck plate are tight, tired
Diagnosis：Hypertension
Treatment：It takes orally, be administered daily 1 time and can control 24 hours.
Finally it should be noted that：The foregoing is only a preferred embodiment of the present invention, is not intended to restrict the invention,
Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, still may be used
To modify to the technical solution recorded in foregoing embodiments or carry out equivalent replacement to which part technical characteristic,
All within the spirits and principles of the present invention, any modification, equivalent replacement, improvement and so on should be included in the present invention's
Within protection domain.
Claims (4)
1. ginseng oyster particle, which is characterized in that by the raw material compositing formula of following parts by weight：Ginseng 30-50, oyster 30-50,
Pueraria lobata 30-50, peach kernel 30-50, zaocys dhumnade 30-50, lily 30-50, dark plum 30-50, abdomen snake 30-50, root of Dahurain angelica 30-50, Chinese cassia tree
30-50, raspberry 30-50, Qiang worm 100-120, Moschus 2-4, safflower 10-30.
2. ginseng oyster particle according to claim 1, which is characterized in that by the raw material compositing formula of following parts by weight：
Ginseng 30, oyster 30, pueraria lobata 30, peach kernel 40, zaocys dhumnade 30, lily 30, dark plum 30, abdomen snake 30, the root of Dahurain angelica 30, Chinese cassia tree 30 cover basin
Son 30, Qiang worm 100, Moschus 2, safflower 10.
3. ginseng oyster particle according to claim 1, which is characterized in that by the raw material compositing formula of following parts by weight：
Ginseng 50, oyster 50, pueraria lobata 50, peach kernel 50, zaocys dhumnade 50, lily 50, dark plum 50, abdomen snake 50, the root of Dahurain angelica 50, Chinese cassia tree 50 cover basin
Son 50, Qiang worm 120, Moschus 4, safflower 30.
4. ginseng oyster particle according to claim 1, which is characterized in that by the raw material compositing formula of following parts by weight：
Ginseng 40, oyster 40, pueraria lobata 40, peach kernel 40, zaocys dhumnade 40, lily 40, dark plum 40, abdomen snake 40, the root of Dahurain angelica 40, Chinese cassia tree 40 cover basin
Son 40, Qiang worm 110, Moschus 3, safflower 20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810213350.4A CN108186870A (en) | 2018-03-15 | 2018-03-15 | Ginseng oyster particle |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810213350.4A CN108186870A (en) | 2018-03-15 | 2018-03-15 | Ginseng oyster particle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108186870A true CN108186870A (en) | 2018-06-22 |
Family
ID=62595846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810213350.4A Pending CN108186870A (en) | 2018-03-15 | 2018-03-15 | Ginseng oyster particle |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108186870A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125692A (en) * | 2010-01-13 | 2011-07-20 | 王华明 | Wrapping agent in levo-carnitine wrapping technology and composition of ten series products and preparation method |
| CN105749105A (en) * | 2016-04-08 | 2016-07-13 | 山东健科生物技术有限公司 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN105998639A (en) * | 2016-05-20 | 2016-10-12 | 孙龙喜 | Oral liquid with lipid-decreasing and pressure-decreasing effects and preparation method thereof |
| CN106387158A (en) * | 2016-08-19 | 2017-02-15 | 江西汇仁药业股份有限公司 | Health-care tea and preparation method thereof |
| CN107320555A (en) * | 2017-08-22 | 2017-11-07 | 重庆工商大学 | A kind of pharmaceutical composition with antifatigue effect and its production and use |
-
2018
- 2018-03-15 CN CN201810213350.4A patent/CN108186870A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125692A (en) * | 2010-01-13 | 2011-07-20 | 王华明 | Wrapping agent in levo-carnitine wrapping technology and composition of ten series products and preparation method |
| CN105749105A (en) * | 2016-04-08 | 2016-07-13 | 山东健科生物技术有限公司 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
| CN105998639A (en) * | 2016-05-20 | 2016-10-12 | 孙龙喜 | Oral liquid with lipid-decreasing and pressure-decreasing effects and preparation method thereof |
| CN106387158A (en) * | 2016-08-19 | 2017-02-15 | 江西汇仁药业股份有限公司 | Health-care tea and preparation method thereof |
| CN107320555A (en) * | 2017-08-22 | 2017-11-07 | 重庆工商大学 | A kind of pharmaceutical composition with antifatigue effect and its production and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106038612A (en) | Pharmaceutical composition for protecting eyesight as well as preparation method and application thereof | |
| CN108524673A (en) | A kind of Chinese medicine composition and its application | |
| CN101670056B (en) | Medicament for treating malignant tumor | |
| CN104906540A (en) | Preparation method and application of traditional Chinese medicine ointment for preventing and treating delayed nausea and vomiting caused by chemotherapy | |
| CN101084984A (en) | Porridge with intestines-moistening and eyesight-improving function | |
| CN108186870A (en) | Ginseng oyster particle | |
| CN100431593C (en) | Chinese medicinal formulation for treating hydrocephalus | |
| WO2005074952A1 (en) | Chinese medicine for treatment of irritable bowel sysndrome and the preparation thereof | |
| WO2023168898A1 (en) | Application of traditional chinese medicine composition in preparation of drug for preventing and treating retinitis pigmentosa | |
| CN1205938C (en) | Medicine composition containing polydatin or its salt and its use in preparing medicine | |
| CN107496525B (en) | Traditional Chinese medicine composition for treating cancer pain diseases and application thereof | |
| CN104147196B (en) | A kind ofly treat medicine of child's recurrent oral ulceration and preparation method thereof | |
| CN107929523A (en) | A kind of particles for eliminating phlegm and stopping cough and preparation method thereof | |
| CN108853050A (en) | A kind of pharmaceutical carrier is preparing the application in antidiabetic compositions | |
| CN102335387B (en) | Traditional Chinese medicine composition for treating liver stagnation, improving appetite and promoting digestion and preparation method thereof | |
| CN110448618A (en) | A kind of Chinese medicine preparation and preparation method thereof for treating eyesight | |
| CN105412572A (en) | Traditional Chinese medicine composition for treating heart and spleen heat accumulation recurrent oral ulceration | |
| CN111166849A (en) | Medicated bath composition for removing fatigue and improving sleep | |
| CN1763069A (en) | Gen-seng saponin Rg2 preparation method, its pharmaceutical composition and uses in pharmacy | |
| Lewin et al. | Anorexia due to brain injury | |
| CN114949135B (en) | Traditional Chinese medicine composition for treating digestive tract reaction after chemotherapy and preparation method thereof | |
| CN1582984A (en) | Frozen dry powder injection of astrogalus root and its preparing method | |
| CN114272300B (en) | Pharmaceutical composition for improving cerebral ischemia and application thereof | |
| CN108042748A (en) | A kind of drug and preparation method for treating brain tumor | |
| CN100337679C (en) | Chinese traditional medicine capable of invigorating yang and strengthening qi and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180622 |
|
| RJ01 | Rejection of invention patent application after publication |